TSC1 and neoplasm: Both cellular and animal models demonstrated that pharmacological inhibition of mTORC1 or downregulation of ST6GALNAC1 effectively alleviated the aberrant PD-L1 glycosylation caused by TSC1 deficiency, thereby restoring the function of tumor-infiltrating CD8+ T cells and suppressing tumor progression.